Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment

被引:11
|
作者
Kawata, N [1 ]
Yagasaki, H [1 ]
Yuge, H [1 ]
Nakanoya, Y [1 ]
Fujimura, K [1 ]
Sugimoto, S [1 ]
Hirakata, H [1 ]
Takimoto, Y [1 ]
机构
[1] Nihon Univ, Sch Med, Dept Urol, Surugadai Nihon Univ Hosp,Chiyoda Ku, Tokyo 1018309, Japan
关键词
angiogenesis; Factor VIII-related antigen; localized renal cell carcinoma; postoperative recurrence; thymidine phosphorylase;
D O I
10.1046/j.1442-2042.2001.00299.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied. Method: Of the 71 patients who underwent surgery, 54 patients had no neoadjuvant therapy (group 1), 10 patients were preoperatively administered IFN-gamma (group 2), and the remaining seven patients preoperatively received IFN-gamma and transarterial embolization (group 3). Both TP and Factor VIII immunostaining were performed on formalin-fixed, paraffin-embedded archival tissue from 71 renal cell carcinoma specimens, while TIL immunostaining was performed on frozen sections. Positive immunostaining was quantitatively scored by a computer-assisted digital image analysis. For TIL, positive results were semiquantitatively scored. Results: A significant difference in the recurrence-free rate was recognized for Groups 1, 2 and 3 (P < 0.05). Therefore, the median TP-positive rate (PR), VIII-PR, number of microvessels and positive mean vascular area levels were investigated, between the recurrence cases (n = 6) and the recurrence-free cases (n = 11). Only the TP-PR levels showed a significant difference among them (P = 0.044). In regards to the neoadjuvant cases, a significant correlation was observed between both VIII-PR and CD4 (r = 0.815) as well as between VIII-PR and CD11b (r = 0.756). Conclusion: There was no clear evidence that the neoadjuvant treatment would increase the recurrence-free survival in patients with localized renal cell carcinoma. TP-PR might be a predictor of postoperative recurrence in patients with localized renal cell carcinoma.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [31] Influence of histopathologic factors on pattern of metastasis in squamous cell carcinoma of the head and neck
    Lanzer, Martin
    Gander, Thomas
    Kruse, Astrid
    Luebbers, Heinz-Theo
    Reinisch, Sabine
    LARYNGOSCOPE, 2014, 124 (05): : E160 - E166
  • [32] Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma
    Zhang, Yushi
    Li, Yongqiang
    Deng, Jianhua
    Ji, Zhigang
    Yu, Hongyan
    Li, Hanzhong
    PLOS ONE, 2015, 10 (02):
  • [33] Angiogenesis and angiogenic inhibitors in renal cell carcinoma
    Sawhney R.
    Kabbinavar F.
    Current Urology Reports, 2008, 9 (1) : 26 - 33
  • [34] Renal cell carcinoma : new histopathologic and evolutive renal entities
    Kammerer-Jacquet, S. -F.
    Thierry, S.
    Rioux-Leclercq, N.
    ONCOLOGIE, 2018, 20 (7-12) : 193 - 198
  • [35] Multiple factors influence decision making for the surgical treatment in patients with renal cell carcinoma
    Dahlin, Britt-Inger Kroger
    Hlodan, Jan
    Ghaffarpour, Ramin
    Ljungberg, Borje
    SCANDINAVIAN JOURNAL OF UROLOGY, 2024, 59 : 26 - 30
  • [36] TREATMENT TRENDS OF LOCALIZED RENAL CELL CARCINOMA BY HOSPITAL TYPE: AN ANALYSIS OF THE NATIONAL CANCER DATABASE
    Cahn, David
    Handorf, Elizabeth
    Edwards, Daniel
    Kidd, Laura
    Geynisman, Daniel
    Kadow, Brian
    Greenberg, Richard
    Viterbo, Rosalia
    Chen, David
    Kutikov, Alexander
    Uzzo, Robert
    Smaldone, Marc
    JOURNAL OF UROLOGY, 2018, 199 (04): : E157 - E158
  • [37] Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
    Mattila, Kalle E.
    Vainio, Paula
    Jaakkola, Panu M.
    CANCERS, 2022, 14 (01)
  • [38] Surgery of localized renal cell carcinoma
    Schnoeller, T. J.
    Schrader, M.
    Jentzmik, F.
    ONKOLOGE, 2015, 21 (01): : 22 - +
  • [39] Clinically Localized Renal Cell Carcinoma: Which is the Best Treatment Strategy?
    Borghesi, Marco
    Brunocilla, Eugenio
    Schiavina, Riccardo
    Martorana, Giuseppe
    CLINICAL GENITOURINARY CANCER, 2014, 12 (02) : E61 - E61
  • [40] Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma
    Campbell, Scott P.
    Song, Daniel Y.
    Pierorazio, PhillipM.
    Allaf, Mohamad E.
    Gorin, Michael A.
    JOURNAL OF ONCOLOGY, 2015, 2015